A Prospective, Multi-center Registry for Patients with Short Bowel Syndrome
Registry for Patients with Short Bowel Syndrome
Sponsor: Shire-NPS Pharmaceuticals, Inc
Enrolling: Male and Female Patients
IRB Number: AAAR6066
U.S. Govt. ID: NCT01990040
Contact: Shilpa Ravella, MD: 212-305-3839 / sr3236@cumc.columbia.edu
Additional Study Information: This is a global prospective, observational, multi-center registry to evaluate the long-term safety profile for patients with short bowel syndrome (SBS) who are treated with teduglutide in a routine clinical setting. The registry will also evaluate the long-term clinical outcomes in patients with SBS. SBS patients treated and not treated with teduglutide will be enrolled.
This study is closed
Investigator
Shilpa Ravella, MD
Do You Qualify?
Do you or your child have Short Bowel Syndrome (SBS)? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder


CAPTCHA
Image CAPTCHA
Enter the characters shown in the image.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Cancel
For more information, please contact:
Shilpa Ravella, MD
sr3236@cumc.columbia.edu
212-305-3839
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE